Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature
Angela Y Moore, Blakely S RichardsonArlington Center for Dermatology, Arlington, Texas, USAAbstract: Psoriasis is a chronic T-cell-mediated inflammatory disease that primarily affects the skin and joints. Patients with moderate to severe psoriasis constitute about 30% of the psoriasis population. Tr...
Saved in:
Main Authors: | Angela Y Moore (Author), Blakely S Richardson (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2010-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2023) -
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2023) -
Comparision of the efficacy and safety between Secukinumab and Adalimumab in the treatment of the moderate to severe plaque psoriasis
by: Dandan HU, et al.
Published: (2023) -
Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis
by: Nicolazzo D, et al.
Published: (2014) -
Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis
by: Richard B. Warren, et al.
Published: (2024)